Cogent Biosciences develops targeted therapeutics for patients suffering from rare diseases, focusing particularly on systemic mastocytosis and gastrointestinal stromal tumors (GIST). By leveraging cutting-edge research and clinical trials, we aim to provide innovative and effective treatment options that address significant unmet medical needs. Our commitment to advancing biotechnology positions us as a distinct player in the competitive landscape of biopharmaceuticals.
